Objectives-To determine the feasibility of obtaining intraoperative contrastenhanced ultrasound (CEUS) imaging in patients undergoing open partial nephrectomy for renal cancer. We hypothesize that the study was feasible and the addition of CEUS would improve lesion identification and characterization.
T he standard of preoperative staging renal cell cancer is computed tomography (CT) and magnetic resonance imaging (MRI). Both require intravenous contrast, cannot be performed during surgery for real-time guidance, and have slightly poorer spatial resolution compared with ultrasound. Additionally, contrast-enhanced ultrasound (CEUS) has been shown to be more accurate than non-CEUS, has comparable diagnostic accuracy to CT and MRI, and has only a slight decrease in specificity compared with MRI when evaluating indeterminate cystic renal lesions in the preoperative setting. [1] [2] [3] Furthermore, ultrasound performed during open partial nephrectomy for renal cell cancer can better delineate the exact extent of the cancer in relation to the renal sinus, and show multifocal tumors otherwise unsuspected preoperatively. 4 To our knowledge, little is known about the addition of CEUS for renal imaging in the intraoperative setting. Intraoperative CEUS (IO-CEUS) has been used in liver imaging, demonstrating improved lesion detection and characterization compared with CT or MRI. 5, 6 At our institution, it is standard procedure to perform an intraoperative ultrasound during open partial nephrectomy to evaluate the extent of tumor involvement and detect additional unexpected lesions, thereby guiding surgical intervention. We hypothesize that the addition of IO-CEUS would improve lesion detection and characterization, and thus potentially alter surgical management.
The safety of ultrasound microbubble contrast has been studied by the US Food and Drug Administration (FDA). It has been approved for routine use in echocardiography, but not for radiology at the time of this study. Recently, the FDA approved the CEUS agent Lumason (Bracco Diagnostics, Monroe Township, NJ) for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients, but not for the kidneys. Our primary objective was to perform a feasibility study using IO-CEUS for renal mass detection and characterization in patients scheduled for open partial nephrectomy. Feasibility was defined as the successful capture of IO-CEUS images in 8 of 10 patients. The second primary objective was to reaffirm the safety and dosing of the ultrasound contrast agent, Definity (Lantheus Medical Imaging, Billerica, MA), for use in IO-CEUS. The secondary objective was to also assess the image quality of the CEUS versus baseline non-CEUS of the kidney and mass. The efficacy is defined as 6 of 10 cases as having better image quality on the CEUS versus baseline exam, as determined by the investigators.
Materials and Methods
Approval was obtained from the FDA and institutional review board for this research. Informed consent was also obtained from each patient participating in the study. The study population consisted of 10 Study Drug 1. Ultrasound contrast agent, Definity; 2. Dose of 10 lL/kg of activated Definity, maximum dose of 20 lL/kg; and 3. Slow bolus intravenous contrast injection followed with saline flush.
Study Procedure
After dissection and exposure of the kidney by the surgeon, a baseline intraoperative non-CEUS was performed by the radiologist to evaluate the renal mass, the extent of its involvement in relation to the renal sinus fat, collecting structures and major blood vessels, and to detect any additional unsuspected suspicious lesions. A Philips iU22 ultrasound machine (Philips Healthcare, Bothell, WA) was used, using real-time, gray scale and color Doppler imaging. The transducers consisted of a C8-4 endocavitary, L9-3 linear, or other appropriate probes, which were prepped and covered in a sterile fashion. Following the bolus administration of contrast, the mass and involved kidney were re-imaged.
Static and cine clips of the pre-and post-contrast enhanced images of the mass and involved kidney were documented and stored in the patient's electronic medical record. Pulse inversion harmonic imaging scanning mode was used, which results in improved resolution and sensitivity of contrast microbubbles. 8 A contrast timer was started at the end of the saline flush. Low mechanic index of 0.05 to 0.06 was used after the injection of contrast to preserve the longevity of the microbubbles. A split-screen display of B-mode and CEUS images was used for viewing during contrast administration. Note that in split-screen mode, a low mechanic index setting was used for both the simultaneous Bmode and CEUS images to limit microbubble destruction. This results in poorer (more noise) split-screen Bmode images than regular full quality B-mode imaging. The captured images were reviewed and scored in consensus intraoperatively by the operating surgeon and two radiologists. Lesions were scored for image quality, lesion conspicuity/contrast, lesion vascularity, lesion morphology, lesion echotexture, and additional lesions discovered. The scores ranged from 1 5 poor, 2 5 acceptable, 3 5 good, and 4 5 excellent. Feasibility was defined as successful capture of the contrast-enhanced images in 8 of 10 patients, thus meeting the primary objective of the study. Successful capture of the images was when we were able to perform the exam and obtain diagnostic quality images. Efficacy was defined as more than 6 of 10 cases demonstrating better lesion image quality following contrast injection versus the noncontrast study.
The addition of the CEUS took an added 5 to 10 minutes of surgical time. Scanning time focused on the mass, and the remainder of the kidney took 2 to 4 minutes. The remainder of the 5 to 10 minutes was spent on contrast-enabled transducer preparation, discussion/review of the case by the investigators, and scoring of the findings that were all done intraoperatively.
Vitals signs and adverse events were monitored and recorded after ultrasound contrast injection intraoperatively. Adverse events were also assessed 25 to 35 days after the surgery.
Results
Ten of 11 patients successfully completed the IO-CEUS examination. One study was canceled intraoperatively as a result of a complicated surgery. The study population consisted of 5 men and 5 women, ranging in age from 30 to 78 years. Tumor size ranged from 1.3 to 4.2 cm, and all lesions were solid. No additional lesion was found on CEUS compared with baseline. Pathology from the resected tumors revealed predominantly renal cell carcinoma and one renal oncocytoma (Table 1) .
Image quality was found to be better on the baseline compared with the CEUS images for most of the patients (7 of 10). The image quality on the CEUS images were degraded as a result of structured noise in the form of curved lines moving in waves when using an endocavity probe (Figure 1 ). However, image quality improved, as there was less noise with the use of a linear transducer (Figure 2) . Six of 10 patients showed improved lesion conspicuity, contrast, and vascularity on the CEUS images ( Figures 3 and 4 and Table 2 ). Surgical management did not change with the addition of IO-CEUS.
Vital signs did not change after ultrasound contrast injection. A 25-to 35-day postsurgical assessment for adverse events revealed none.
Discussion
Our feasibility study of IO-CEUS was safe for the 10 patients who underwent open partial nephrectomy for renal mass. Contrast-enhanced ultrasound has a proven track record for being safe for use. 9 Reported transient side effects included low back pain, flank pain, trembling, fever, rashes, hypotensive episodes, leukocytosis, facial flushing, tingling sensation at cannulated extremity, headache, mild vomiting, lethargy, mild supraventricular tachycardia in chronic obstructive pulmonary disease patients, mild allergy symptoms, and increased liver enzymes.
10-13 None of our 10 patients reported any of Figure 2 . Improved image quality with less noise on the CEUS image (A) compared with the baseline (B) when a L9-3 linear transducer was used, enabling better identification of the lesion (arrow). However, the L9-3 was limited as a result of its large size in a small operative opening. these or other side effects. Multiple previous studies also found CEUS to be safe with low rate of side effects. 9 When used for echocardiography, the risk was found to be 0.062%. 14 Additionally, Piscaglia et al reported a serious adverse rate of 0.0086% in a large retrospective analysis of 23,188 investigations for ultrasound contrast agent SonoVue (Bracco Spa, Milan, Italy) in abdominal examinations. 15 Second, our study demonstrates that IO-CEUS is feasible for patients undergoing open partial nephrectomy for renal mass. All 10 patients had diagnostic IO-CEUS. The dissected and exposed kidney with a mass allowed IO-CEUS to be performed successfully in a short amount of time (5-10 minutes) without significantly adding increased surgical duration. Similarly, IO-CEUS has shown feasibility and success with liver, pancreas, and intracranial surgery. [16] [17] [18] Furthermore, IO-CEUS was recently performed successfully to facilitate selective ischemia for robotic assisted laparoscopic partial nephrectomy. 19 However, our study was not efficacious. Only 3 of 10 patients showed better image quality on the CEUS versus baseline (Table 2) . At the time of our study, only the C8-4 endocavitary and L9-3 linear transducers were available for use on the Philips IU22 ultrasound machine with contrast function and that would fit through the incision into the operative field. Initially, the C8-4 endocavitary probe was used for its easier fit in the operative field. However, with contrast function turned on, images obtained from the C8-4 endocavitary probe resulted in structured noise (Figure 1) . The images were therefore poor compared with the baseline. The larger L9-3 transducer provided better image quality with contrast function, but it was more difficult to manipulate in the operative field because of its size, resulting in limited use ( Figure 2 ). Although our study was not efficacious as a result of limitations in optimal probe availability at the time, it showed improved lesion contrast and vascularity ( Figures 3-5 and Table 2 ). The vascular nature of the tumors were better appreciated on the CEUS compared with the color Doppler on the baseline. The wash-in and wash-out characteristics of the purely intravascular microbubbles about the tumor were clearly delineated.
The limitation at the time of our study was the lack of an available optimal transducer with contrast function for use in the small surgical field of an open partial nephrectomy. Nevertheless, even with the limited availability of a transducer at the time, the study showed that IO-CEUS is beneficial for better identifying and characterizing the renal masses, was safe for our 10 patients, and is feasible. Future availability of a small transducer with contrast function for use with the IU22 ultrasound machine would no doubt be efficacious for use in the intraoperative setting-not just for renal masses, but other organs as well. Another limitation of our study was the small number of patients (10 total), as this was a feasibility study. Future studies with a larger number of patients would again likely lead to better insights for IO-CEUS with regard to renal mass imaging.
